Abraxane in Combination With Bevacizumab Promising in Treating Breast Cancer

Abraxis BioScience, Inc., announced study results Tuesday that demonstrate a regimen of Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin) may have potential in the treatment of triple-negative breast cancers.
Trading Markets